ROCHE, rate on Zealand Pharma drugs on $ 5.3 billion

Copenhagen, Denmark Rosh concluded an agreement for $ 5.3 billion on Danish biotechnology Zealand formCandidate for weight loss “next generation”.

The transaction announced in March and closed in the second quarter Novo nordisk and Eli LilyAfter creating a portfolio of obesity treatment in recent years.

Analogue Petrel Amelin Zealand Pharma can become an asset that distinguishes it. Analogues of amilin are the form of weight loss treatment, which mimics the hormone joint with insulin in the pancreas to increase saturation. This is different from the commonly common GLP-1 drugs such as Zepbound and Wegovy, which mimic the hormones formed in the gut to suppress appetite.

But while analysts saw Rosh as an early petrel contender, both firms insisted that this was not done.

“It was a very competitive process, with a number of parties to the end,” said CNBC David Kendal, Chief Physician Zealand Pharma.

Early clinical data indicate a comparable weight loss between amiline and GLP-1 analogues, but with potentially superior tolerability and muscle preservation among the previous-now key points for the industry.

Zealand was named Petrelintide “Future Basics Therapy” To control weight, while Bofa called it “potentially the best in the AMILL class”, focusing on 15-20% phase 3 weight loss as monotherapy.

“Roche was not the only company that saw this appeal,” said the head of the development of global therapy and cardiovascular, cardiovascular, cardiovascular, renal and metabolism (CVRM), CNBC said.

“These things are never done until the pen falls into the paper.”

The Roche-Zealand deal to see both companies joint development and commercialization Petrelintide both autonomous treatment as well as combo-therapy with the leading intake asset Roche CT-388. According to the terms, Zealand will receive previous cash payments of $ 1.65 billion, and the potential for milestones, which reached a total of up to $ 5.3 billion, depending on phase 3 testing and sales development.

At the time, it was announced as a victory in Zealand, and analysts referred to strong conditions for smaller biotechnology. Zealand Pharma shares jumped 38% A day of deal, while Rosh added about 4%

“We view this as the best scenario for Zealand,” Bofa Global Research writes in a note on March 13, the day after the announcement, saying that the transaction noted all biotechnology – and its own partnership boxes. The bank also called it a “positive” for Rosh, entering AMILIN into its wider portfolio of obesity.

Kendal Zealand told CNBC that 50-50 joint development, the nature of the affiliate communication, was a “important” part of the negotiations that which It began seriously in September.

“We pushed the sa-ko,” Kendal said. “Others could say this, but when the pencil got into the paper, it didn’t read it very much. We bring experience in Petrelntide, they bring the commercial side.”

Have been raised in doubt about whether Zealand could reach its target earnings after earlier Abbvie A drug with obesity in the gobra A licensing transaction I saw that the latter agrees to receive certain fees for world clean sales. However, both Rosh and Zealand insisted that their conditions were bilateral victories.

“The point is not that it was a victory for Zealand. It is not overwhelming on their way or on our way. It’s a real partnership,” Chakravi said. “If you have real cooperation and smooth skin in the game, here is the magic.”

The company was executed last year after the trial results for one of such experimental weight loss pills, CT-996, was associated with temporary side effects. However, Rosh has long insisted that his attention is paid Create a set of weight loss therapyWith analogues of amilin among key goals.

“Although we had a good profile in the intake, it was also clear that there was heterogeneity in this,” Chakravi said. “We asked what we could do for people who want to reduce weight loss? AMININA goes to the top. Then we asked that the companies were working in this space. This assessment brought us to Zealand.”

After seven months of negotiations, including other major pharmaceutical players, both firms eventually led a strong scientific and cultural form among the key causes of the agreement.

“It came down before we see things scientifically. Can we talk about science to the eyes. It was very clear that Zealand saw things exactly as I described it,” Chakarov said, calling the currently dissatisfied with patients, such as established weight loss.

“Rosh was loved throughout the way in terms of culture,” said Christina Sonnenborg Bradal, Chief Director of the People’s People Zealand Pharma.

Now the race for drug development. Zealand Last week The start of the 2B phase test on Petrolinths in overweight or obesity and type 2 diabetes, and the results in the summer of 2026 are announced. Phase 3 tests will then be held.

This happens when Novo Nordisk fights to shake the negative moods after a row Disappointing results of the trial For his own analog candidate for AMIL CAGRISEMA, which combines the CAGRULINT with its signature Semaglutid – the active ingredient in Wegovy.

CEO ZEAland Adam Stinsberg said CNBC In October, it expects to bring Petrelintide to the market in 2030. This can be left over the focused term Novo Nordisk 2026 to regulate Cagrisema approval. But with Rosh now on board, Zealand said the term could come forward.

“We do our best to accelerate?” Kendal asked. “Yes.”

However, the competition continues to heat up in the fast -growing drug market. Last month Eli Lily said her Daily pill with obesity Orforglipron He decided his goals in the first of several tests in the late stage, potentially opening the door for convenient and easier in the production of oral weight. The Gubra ABBVIie transaction also brings another candidates to AMILIN, although its development remains at Petrelntide.

Meanwhile, analysts note the entry barriers for new entrants, given the high development costs associated with such drugs, and the need to demonstrate additional or excellent benefits.

“We don’t have much luxury time to bring it forward,” Chakravi said. “We are definitely striving for a shorter horizon.”